Paasa Logo
Lineage Cell Therapeutics, Inc. logo
LCTXAMEXMarket closedOpens 9:30am ET

Lineage Cell Therapeutics, Inc.

$0.95Last updated
-$0.02 (2.42%)Past day
Timezone

Lineage Cell Therapeutics, Inc. (AMEX: LCTX) is trading at $0.95, about ₹91 at today's USD/INR rate, as of 29 Sep 2026, 4:00 PM ET, down 2.42% today. Indian residents can buy Lineage Cell Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$0.99
Previous close:$0.97
Volume:2.59M

Today's low

$0.92

Today's high

$0.99

52 week low

$0.91

52 week high

$2.09

LCTX opened at $0.99, closed previously at $0.97, and has traded between $0.91 and $2.09 over the past 52 weeks.

About

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Country
US
CEO
Brian Culley
Exchange listed on
AMEX
Industry
Biotechnology
Base currency
USD
Full Time Employees
75
Sector
Healthcare
IPO date
05/03/1992

Key statistics

Avg. volume

1.34M

Market cap

$236.21M

P/E Ratio

-6.76

Price-to-sales ratio

18.05

Enterprise value

$345.92M

Free cash flow yield

-5.06%

Debt-to-equity ratio

0.04

Return on equity

-142.61%

ROIC

-19.75%

Beta

1.55

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

$14.56M

Earnings per share

-$0.28

Free cash flow

-$19.44M

Net profit margin

-246.58%

Gross margin

96.59%

EBITDA

-$67.95M

Revenue growth

53.24%

Similar securities

This is not an investment recommendation

How to buy Lineage Cell Therapeutics from India

Indian residents can buy Lineage Cell Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for Lineage Cell Therapeutics and place an order

    Find Lineage Cell Therapeutics by name or by its ticker, LCTX, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Lineage Cell Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Lineage Cell Therapeutics position in USD and INR. Lineage Cell Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Lineage Cell Therapeutics from India

Trading and taxes when buying Lineage Cell Therapeutics from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneLineage Cell Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
US estate tax
May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy Lineage Cell Therapeutics stock?

Yes. Lineage Cell Therapeutics (LCTX) has been listed on NYSE American since 1992, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one Lineage Cell Therapeutics share cost in rupees?

One Lineage Cell Therapeutics share is $0.95 — about ₹91 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the Lineage Cell Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Lineage Cell Therapeutics from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy whole shares of Lineage Cell Therapeutics?

Yes. One Lineage Cell Therapeutics share is $0.95, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Lineage Cell Therapeutics.

How are gains on Lineage Cell Therapeutics shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Lineage Cell Therapeutics price. Paasa issues a capital-gains statement for your return.

Does Lineage Cell Therapeutics pay a dividend?

No. Lineage Cell Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Lineage Cell Therapeutics from India?

NYSE American trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is there estate or inheritance tax on Lineage Cell Therapeutics shares held from India?

US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.

Do I have to declare Lineage Cell Therapeutics shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Lineage Cell Therapeutics holding, its cost and its closing value.

How do I sell Lineage Cell Therapeutics and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.